Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia

Mrinal M. Patnaik, David A. Sallman, Abhishek A. Mangaonkar, Rachel Heuer, Jeffery Hirvela, Darci Zblewski, Aref Al-Kali, Moritz Binder, Maria E. Balasis, Hannah Newman, Christopher Letson, Traci L. Kruer, Naseema Gangat, Rami S. Komrokji, Ayalew Tefferi, Adrian Lo, Ted Shih, Cameron Durrant, Alan F. List, Eric Padron

Research output: Contribution to journalArticle

4 Scopus citations
Original languageEnglish (US)
Pages (from-to)909-913
Number of pages5
JournalBlood
Volume136
Issue number7
DOIs
StatePublished - Aug 13 2020

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Patnaik, M. M., Sallman, D. A., Mangaonkar, A. A., Heuer, R., Hirvela, J., Zblewski, D., Al-Kali, A., Binder, M., Balasis, M. E., Newman, H., Letson, C., Kruer, T. L., Gangat, N., Komrokji, R. S., Tefferi, A., Lo, A., Shih, T., Durrant, C., List, A. F., & Padron, E. (2020). Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood, 136(7), 909-913. https://doi.org/10.1182/blood.2019004352